

首页 期刊概况 编委会 期刊内容 特邀审稿 投稿指南 出版发行

205~209.CAR的表达调节对肝癌基因治疗中腺病毒载体感染效率的影响[J].吴 赟,郑 辉,陈宏新,黄孝天,沈佐君,刘晶星.中国肿瘤生物治疗杂志,2008,15(3)

CAR的表达调节对肝癌基因治疗中腺病毒载体感染效率的影响 点此下载全文

## 吴 赟 郑 辉 陈宏新 黄孝天 沈佐君 刘晶星

1.安徽医科大学 附属省立医院 临检中心, 合肥 230001; 2. 上海交通大学医学院 病原生物学教研室, 上海 200025; 1. 安徽医科大学 附属省立医院临检中心, 合肥 230001; 2. 上海交通大学医学院 病原生物学教研室, 上海 200025

基金项目: 国家自然科学基金资助项目(No.39970691)

DOI: 10.3872/j.issn.1007-385X.2008.3.002

摘要

目的:通过抑制Raf MEK ERK信号转导途径调节肝癌细胞表面柯萨奇病毒和腺病毒受体(coxsackie adenovirus receptor,CAR)的表达,探索肝癌基因治疗中CA R表达与腺病毒(adenovirus, Ad)感染效率之间的关系。方法:选择两株人肝癌细胞株SMMC-7721及HepG2,以Raf MEK ERK信号转导抑制剂U0126作用后,应用 Western blotting检测细胞表面CAR蛋白的表达水平。选用能表达GFP的非复制型E 1A缺陷的Ad感染人肝癌细胞SMMC-7721及HepG2,应用FACS分析U0126处理前后Ad感染效率的变化。结果:细胞经MEK抑制剂U0126处理后,细胞膜表面CAR的表达呈明显上调趋势。FACS检测显示。经U0126处理后,在相同感染复数(10 MOI)Ad GFP的感染下,GFP +细胞率明显升高,SMMC 7721细胞由(71.65±6.21)%上升至(86.54±5.70)%;HepG 2细胞由(77.53±4.62)%上升至(87.06±2.83)%(均P<0.05)。结论:抑制剂U0126抑制Raf MEK ERK信号转导途径后,可上调肝癌细胞膜表面CAR的表达,从而导致Ad在肝癌细胞感染效率的提高。

关键词: 柯萨奇病毒和腺病毒受体 U0126 腺病毒 感染效率 肝细胞癌 基因治疗

Influence of coxsackie adenovirus receptor expression on infection efficiency of adenovirus vector in gene therapy of hepatocellular carcinoma Download Fulltext

WU Yun ZHENG Hui CHEN Hong xin HUANG Xiao tian SHEN Zuo jun LIU Jing xing

1.Center of Clinical Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China; 2. Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 1.Center of Clinical Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 1.Center of Clinical Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China; 2. Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai 200025, China; 2.Department of Etiology, School of Medicine, Shanghai 200025, China; 2.Department

Fund Project: Supported by the National Natural Science Foundation of China (No. 39970691).

## Abstract

To explore the relationship between coxsackie adenovirus receptor (CAR) expression and the infection efficiency of adenovirus vector in gene therapy for hepatocellular carcinoma through regulating CAR expression on cells surface via inhibition of the Raf/MEK/ERK pathway. Methods: Western blotting analysis was used to examine CAR expression in hepatocellular carcinoma cells (SMMC-7721 and HepG 2) before and after treatment with U0126, inhibitor of Raf/MEK/ERK signal transduction. SMMC-7721 and HepG 2 were infected by a non replicating, E1A deleted adenovirus expressing EGFP (Ad-GFP). FACS was used to analyze the infection efficiency of Ad before and after U0126 treatment. Results: The expression of CAR on cell surface had an increasing tendency after treatment with U0126. FACS analysis showed significantly increased infectivity of cells treated with the MEK inhibitor U0126 compared with untreated cells: SMMC-7721, (71.65 $\pm$ 6.21) % $\rightarrow$  (86.54 $\pm$ 5.70) %, HepG 2, (77.53 $\pm$ 4.62) % $\rightarrow$  (87.06 $\pm$ 2.83) %, when infected with Ad GFP at the same MOI (10 MOI). Conclusion: The inhibition of Raf/MEK/ERK pathway by U0126 may up regulate the expression of CAR in some hepatocellular carcinoma cells, which subsequently enhances the susceptibility of adenovirus infection to target cells.

Keywords:coxsackie adenovirus receptor U0126 adenovirus infection efficiency hepatocellular carcinoma gene therapy

查看全文 查看/发表评论 下载PDF阅读器

Copyright © **Biother.Org™** All Rights Reserved; ISSN: 1007-385X CN 31-1725 主管单位: 中国科学技术协会 主办单位: 中国免疫学会、中国抗癌学会 地址: 上海市杨浦区翔殷路800号 邮政编码: 200433 京ICP备06011393号-2 本系统由北京勤云科技发展有限公司设计